- Knight Therapeutics reported a 12% year-over-year increase in revenue for the second quarter, reaching C$107.4 million, surpassing the estimated C$95.7 million.
- The company’s gross margin decreased to 42% compared to 50% in the previous year, and was lower than the estimated 47%.
- Adjusted EBITDA was reported at C$15.5 million, a slight decrease of 1.5% year-over-year, but exceeded the estimate of C$12.6 million.
- Knight Therapeutics reported a loss per share of C$0.13, compared to a loss per share of C$0.020 in the previous year, against an estimated earnings per share of C$0.02.
- The company’s stock is rated with 6 buys, 1 hold, and 0 sells by analysts.
A look at Knight Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Knight Therapeutics Inc. shows a promising long-term outlook. With high scores in Value and Growth, the company is positioned well for potential future success. Its strong focus on acquiring and licensing pharmaceutical products indicates a solid foundation for growth and value creation in the industry.
While Knight Therapeutics scores lower in Dividend and Momentum, its resilience score of 4 suggests that the company has the ability to withstand challenges and adapt to market dynamics effectively. Overall, Knight Therapeutics Inc. is well-positioned in the healthcare industry with a diverse portfolio of products catering to global markets.
Summary: Knight Therapeutics Inc. is a specialty pharmaceutical company that acquires and licenses pharmaceutical products, offering its innovative solutions to the healthcare industry worldwide.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
